(Q33357914)
Statements
A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies (English)
Bahram Forouzesh
Chris H Takimoto
Andrew Goetz
Sami Diab
Lisa A Hammond
Leslie Smetzer
Garry Schwartz
Robert Gazak
John T Callaghan
Daniel D Von Hoff
Eric K Rowinsky
1 November 2003